Prognostic Factors in Lenvatinib-Treated Differentiated Thyroid Cancer: A Real-World Study with Extended Follow-Up
European Thyroid Journal · 12.11.2026
DOI: 10.1530/etj-26-0231 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Thyroid Journal, online erschienen am 12.11.2026. Verfasst von Kiminori Sugino und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Ito Hospital, 4-3-6, Jingumae, Shibuya-ku , Tokyo, Japan. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Lenvatinib is a standard first-line treatment for progressive radioiodine-refractory differentiated thyroid cancer (RAI-R DTC), but real-world outcomes over extended follow-up and prognostic factors remain insufficiently characterized.
Methods
We retrospectively analyzed 97 patients with progressive RAI-R DTC treated with lenvatinib at a single institution between 2015 and 2024. Patients with anaplastic or medullary thyroid carcinoma and those treated for less than six months were excluded. Progression-free survival (PFS) and overall survival (OS) were evaluated using the Kaplan–Meier method, and prognostic factors were assessed using Cox proportional hazards models.
Results
Median age at treatment initiation was 68 years, and 38% of patients had bone metastases. With a median follow-up of 36 months, median PFS and OS were 25 months (95% confidence interval [CI], 21–31) and 59 months (95% CI, 45–82), respectively. The objective response rate was 58%, and the disease control rate was 97%. Multivariate analysis identified older age as an independent predictor of shorter PFS (Hazard ratio [HR] 1.34 per decade of age, p<0.01) and OS (HR 1.63 per decade of age, p<0.005). Bone metastasis was independently associated with worse OS (HR 2.25, p<0.05) but not PFS. Receiver operating characteristic analyses suggested age cutoffs of approximately 70 years. Bone metastasis was associated with significantly poorer OS among older patients.
Conclusions
Lenvatinib provided durable disease control in patients with RAI-R DTC. Older age at treatment initiation and bone metastasis were independent determinants of survival and may help guide risk stratification and treatment timing in clinical practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Ito Hospital, 4-3-6, Jingumae, Shibuya-ku , Tokyo, Japan.
ORCID-Profile: Kiminori Sugino, Chie Masaki
Zitieren
APA
Sugino, K., Matsuzu, K., Kitagawa, W., Tomoda, C., Suzuki, A., Okamura, R., Akaishi, J., Hames, K. Y., Masaki, C., Saito, Y., Yoshioka, K., & Ito, K. (2026). Prognostic Factors in Lenvatinib-Treated Differentiated Thyroid Cancer: A Real-World Study with Extended Follow-Up. European Thyroid Journal. https://doi.org/10.1530/etj-26-0231
Vancouver
Sugino K, Matsuzu K, Kitagawa W, Tomoda C, Suzuki A, Okamura R, et al. Prognostic Factors in Lenvatinib-Treated Differentiated Thyroid Cancer: A Real-World Study with Extended Follow-Up. European Thyroid Journal. 2026. doi:10.1530/etj-26-0231
BibTeX
@article{Sugino2026,
author = {Sugino, Kiminori and Matsuzu, Kenichi and Kitagawa, Wataru and Tomoda, Chisato and Suzuki, Akifumi and Okamura, Ritsuko and Akaishi, Junko and Hames, Kiyomi Yamada and Masaki, Chie and Saito, Yoshiyuki and Yoshioka, Kana and Ito, Koichi},
title = {Prognostic Factors in Lenvatinib-Treated Differentiated Thyroid Cancer: A Real-World Study with Extended Follow-Up},
journal = {European Thyroid Journal},
year = {2026},
doi = {10.1530/etj-26-0231}
}
EUVIMED